Table 4 Clinical-pathological data of the study population, divided in mPDCD1low and mPDCD1high groups
n | Study population, n (%) | mPDCD1low, n (%) | mPDCD1high, n (%) | χ2 test; p | p | |
|---|---|---|---|---|---|---|
Study population | 69 | 69(100.0) | 42(61) | 27(39) | ||
Age, median (range) | 69 | 77 (41-95) | 76(41-90) | 81(50-95) | −2.04 | 0.042§ |
Age > 75 years | 69 | 41(59) | 22(52) | 19(70) | 2.21 | 0.137 |
Male sex | 69 | 38(55) | 26(62) | 12(44) | 2.02 | 0.155 |
Size, median (range) | 65 | 2.5(0–95) | 2.5(0–7) | 2.45(1–9) | −0.11 | 0.909§ |
Size > 2 cm | 69 | 38(55) | 21(50) | 17(63) | 0.29 | 0.330 |
Tumor thickness, mm | 65 | 12(1–45) | 13(3–23) | 11(1–45) | 1.36 | 0.173§ |
Tumor thickness>10 mm | 65 | 37(57) | 23(59) | 14(53.8) | 0.17 | 0.683 |
Angioinvasion | 65 | 38(59) | 25(64) | 13(50) | 1.28 | 0.258 |
Mitosis > 10/HPF | 69 | 40(58) | 23(55) | 17(63) | 0.45 | 0.501 |
Ki67, median (range) | 69 | 60(10-100) | 60(20-100) | 60(10-95) | 0.15 | 0.882* |
Ki67 > 50% | 69 | 42(61) | 26(62) | 16(59) | 0.22 | 0.635 |
MCPyV | 69 | 35(51) | 25(60) | 10(37) | 3.32 | 0.068 |
Immune cells | 69 | 35(51) | 33(79) | 2(7) | <0.001** | |
Infiltrative growth | 65 | 22(34) | 16(41) | 6(23) | 2.24 | 0.134 |
PD-L1 immune cells 5-100% | 69 | 31(45) | 23(55) | 8(30) | 4.20 | 0.041 |
PD-L1 tumor 5-100% | 69 | 24(35) | 16(38) | 8(30) | 0.52 | 0.471 |
PD-L1 global | 69 | 37(54) | 29(69) | 8(30) | 10.27 | 0.001 |
Clinical stage III-IV | 69 | 24(35) | 16(38) | 8(30) | 0.52 | 0.471 |
Site | 69 | 0.161** | ||||
head&neck | 26(38) | 12(17) | 14(20) | |||
Extremities | 28(41) | 19(28) | 9(13) | |||
Trunk | 15(22) | 11(16) | 4(6) |
